A Platinum Open Access Journal for Organic Chemistry

Paper

Free to Authors and Readers | DOAJ Seal | *Arkivoc* **2024** (2) 202312120

Concise total syntheses of lysergene, lysergine, isolysergine and festuclavine

Nikhil R. Tasker and Peter Wipf*


Department of Chemistry, University of Pittsburgh, Pittsburgh PA 15260, USA
Email: pwipf@pitt.edu

In honor of Professor Samir Zard and in celebration of his exceptional creative contributions to organic synthesis

Received 10-27-2023 **Accepted Manuscript** 11-09-2023 **Published on line** 11-18-2023

Abstract

A streamlined synthesis of the tetracyclic ergot alkaloid scaffold enabled the preparation of several clavine alkaloids, including lysergol, isolysergol, lysergine, isolysergine, lysergene, and festuclavine. The mesylation and subsequent elimination or reduction of lysergol and isolysergol building blocks complements and expands previous total syntheses of these natural products. In the course of the preparation of isolysergine, an interesting new cascade process was discovered that led to the formation of a cyclopropanated ergolin-2(3*H*)-one as a spontaneous oxidation product of an intermediate 1,3-dihydrobenzo[*cd*]indole.



lysergine; R^1=CH_3, R^2=H
isolysergine; R^1=H, R^2=CH_3

lysergene

festuclavine

benzo[*cd*]indol-2(1*H*)-one

lysergol; R^1=CH_2OH, R^2=H
isolysergol; R^1=H, R^2=CH_2OH

Keywords: Ergot alkaloids, lysergol, lysergine, isolysergine, lysergene, festuclavine

Cite as *Arkivoc* **2024** (2) 202312120
DOI: https://doi.org/10.24820/ark.5550190.p012.120

©**AUTHOR(S)**

Introduction

The ergot alkaloid family continues to attract vivid interest from synthetic chemists for its structural diversity and complexity as well as for its broad range of physiological effects, often paired with exceptional potency at CNS receptors. Historically, ergot alkaloids have been associated with outbreaks of ergotism and mass hysteria in the middle ages (dancing plague, Salem witch trials) in the West, and, in the East, with lifestock poisonings (drunken horse disease), longevity, and spiritual transcendence.[1,2,3,4] More recently, there is a surge of interest in the medical psychedelic properties of ergot alkaloids, in conjunction with their clinical success in the treatment of depression, anxiety, substance abuse, and obsessive-compulsive disorders.[5] In October 2023, there were 71 active clinical trials with psilocybin, 25 with *N*,*N*-dimethyltryptamine (DMT) and 5-hydroxytryptophan (5-HTP), and 14 trials with lysergic acid diethylamide (LSD).[6]

The first total synthesis of lysergic acid and ergonovine by Woodward in 1954,[7] followed by numerous reports on the total syntheses of these and other ergot metabolites,[1,8,9] clearly established the feasibility of a nature-independent access to these alkaloids that could be used for analog preparation and biological testing. However, the medicinal chemistry field was slow to transfer these advances to medical breakthroughs in the development of psychedelic drugs with attractive pharmacokinetic (PK) and ADME/Tox profiles, undoubtedly in part due to major legal and societal hurdles after lysergic acid and its analogs were removed from lawful circulation in 1966. Furthermore, the accomplished total syntheses were frequently mainly of academic significance and lacked practical value due to their linear nature, number of steps, and limited scope and robustness. Synthetic advances in this field therefore remain highly significant. Clinical research and development of psychedelics is currently mainly limited to legacy compounds, i.e. nature-derived or structurally simple synthetic products from the public domain. In fact, the "paucity of structure–activity data for ergolines principally results from the synthetic difficulty attendant to chemical transformations of the ergolines".[10]

Based on a new approach to indole synthesis[11,12,13] and the application of novel strategic disconnections,[14,15] our group has developed a rapid access to ergot alkaloids, including the synthesis of unnatural stereoisomers, enabling iterative structure-activity relationship (SAR) investigations.[16] Initially, both enantiomers of cycloclavine were prepared in eight steps with two sequential Diels-Alder reactions. Their CNS receptor profiles were compared to the three main agonist chemotypes at the serotonin (5-HT) receptor: tryptamines (and inverse tryptamines), ergolines related to LSD (essentially rigidified tryptamines), and phenethylamines (Figure 1), showcasing the strong stereoselectivity and a distinct structure-activity relationship of the cycloclavines.[16] For example, this work demonstrated for the first time the increased selectivity for serotonin receptors (5-HTRs) of the clavine alkaloid subclass that lacks the carboxyl group that is typical for lysergic acid and LSD derivatives.[16] A key aspect of our synthetic approach was the rapid access to the tetracyclic scaffolds of these natural products. For example, an unprecedented Rh-catalyzed asymmetric cyclopropanation of allene (**1**) with the pentafluoro diazoester **2** was used, followed by aminolysis with vinylogous amide **3** to generate the precursor **4** for a novel intramolecular Diels-Alder reaction of a methylene cyclopropane (IMDAMC) to yield tricyclic indolinone **5** (Scheme 1).[16] (+)-Cycloclavine was obtained in overall 8 steps after a Stahl dehydrogenation of **5**, 1,2-addition of the novel lithium reagent **6** to the resulting enone, an intramolecular furan Diels-Alder reaction (IMDAF), and $LiAlH_4$ reduction of lactam **8**.

 ©AUTHOR(S)





Figure 1. Panel A: Serotonin (5-HT), 5-hydroxytryptophan (5-HTP) and synthetic 5-HTR ligands. Panel B: Lysergic acid and representative ergot (lysergic acid) and clavine (cycloclavine, agroclavine, lysergol, lysergene, festuclavine, lysergine) natural products.


 ©AUTHOR(S)



Scheme 1. Overview of an 8-step asymmetric total synthesis of (+)-cycloclavine.[16]

Our recent 5-step synthesis of lysergol and isolysergol enables the production of both natural products and synthetic analogs.[17] This process takes advantage of a transition metal-free hydrogen autotransfer (HA) alkylation reaction with commercially available **10** and 4-bromoindole **9** to generate intermediate **11** (Scheme 2).[18] Further optimization of this reaction led to a 79% yield on a 4-g reaction scale. After *N*-alkylation of **11** and reduction of the resulting pyridinium salt, **12** proved to be a valuable intermediate for scaffold variation.[17] Isomerization of the alkene results in **13** that is subjected to an intramolecular Heck coupling to provide both methyl lysergate (**14**) and isolysergate (**15**) configurations at C(8). Reduction with $LiAlH_4$ then generates lysergol **16** and isolysergol **17**. The latter two compounds are valuable precursors for the synthesis of other ergot alkaloids **18** (*vide infra*).

 ©**AUTHOR(S)**



Scheme 2. Overview of a 5-step total synthesis of lysergols that serves as a segue to the preparation of other clavine alkaloids **18**.[17]

A panel of 13 pertinent CNS GPCRs was profiled at 10 µM and 1 µM concentration for a comparison of the properties of cycloclavine (CCV), lysergol, and isolysergol enantiomeric pairs (Table 1).[16] The cycloclavines were significantly more selective in this panel than D-LSD, the bioactive LSD stereoisomer, as well as psilocin, the active substance derived from the natural phosphate prodrug psilocybin that is currently being investigated clinically as a treatment for anxiety and depression in cancer care, as well as for enhancement of cognitive flexibility and creativity.[19] (+)-Cycloclavine ((+)-CCV) proved considerably more potent at 5-HT_{1A}R than (–)-cycloclavine (EC_{50}=0.14 µM vs ca. 5 µM for (–)-cycloclavine ((–)-CCV); Table 1). Both CCV stereoisomers are poor activators at 5-HT_{2A}, suggesting that hallucinogenic or strongly euphoric effects in humans might be significantly reduced in comparison to D-LSD. (+)-CCV also displays a potent activation (EC_{50}=16 nM) at 5-HT_{2C}, a receptor that is thought to contribute to the desirable mental effects of psychedelics. None of these agents activated 5-HT_{2B}, a subtype that has been associated with cardiotoxicity. Overall, the 5-HTR profile of (+)-CCV mirrors that of psilocin with the exception of agonist effects at 5-HT_{2A} and is substantially different from the strongly hallucinogenic D-LSD, which bodes well for future therapeutic investigations of the clavine compound class. Substitution at the indole ring, or stereochemical variations in the scaffold of the clavine alkaloid (+)-lysergol can further enhance the selectivity among 5-HT receptors compared to D-LSD. Strong stereochemical preferences are also apparent in the receptor profile of the (iso)lysergols (Table 1), and the data confirm that further structural modifications to decrease 5-HT_{2C} binding and increase 5-HT_{1A} affinity are feasible. These and

 ©**AUTHOR(S)**

other structure-activity relationships are currently being investigated, and the potential utility of these compounds in an exploratory disease model will be reported in due course.


Table 1. Effects of cycloclavines (CCVs), lysergols, isolysergols, psilocin, and D-LSD as a function of specific agonist radioligand binding to selected 5-HTRs [μM][a,b 16]

Receptor	(+) / (–)-CCV[b]	(+) / (–)-Lysergol[b]	(+) / (–)-Isolysergol[b]	Psilocin[b,c]	D-LSD[b,c]
5-HT_{1A}	0.14 / 5	0.1 / >2	0.1 / >2	0.123[c,d]	0.003[c,d]
5-HT_{2A}	10 / >50	1.5 / >2	>2 / >2	0.721	0.261
5-HT_{2B}	>20 / >20	>5 / >2	>2 / >2	>20	12
5-HT_{2C}	0.016 / 3.2	0.005 / 1	0.1 / >2	0.094[c,d]	0.015[c,d]

[a]Assays were performed in duplicate at human receptors (5-point CRCs); [b]activation potency EC_{50} values [μM], unless otherwise specified; [c]literature data; [d]K_i.

Results and Discussion

The efficient synthesis of ergolines **14**-**17** allowed for the possibility to extend the preparation of lysergols to other clavine alkaloids with the general structure **18**. Specifically, mesylation of lysergol **16** provided **19** in quantitative yield, and subsequent elimination with KO-*t*-Bu led to lysergene (**20**) in 61% yield (Scheme 3). The mesylate **19** could also be reduced with $LiAlH_4$ in THF at reflux to furnish lysergine (**21**) in 56% yield. This alkaloid was converted to festuclavine (**22**) by treatment with Pd/C and H_2 gas, selectively installing the favored *trans*-ring junction in 93% yield.




Scheme 3. Syntheses of (±)-lysergene (**20**), (±)-lysergine (**21**), and (±)-festuclavine (**22**) from (±)-lysergol (**16**).

Previous preparations of lysergene,[20] lysergine[21] and festuclavine[22] used different precursors and reaction protocols, and access to these ergot alkaloids was mainly accomplished by means of formal syntheses from more readily available, isolated natural products. Lysergene, f. ex., has been prepared by a dehydration of the

 ©**AUTHOR(S)**

tertiary alcohol in setoclavine[23] and by a Wittig methylenation of a lysergic acid derivative.[24] The reduction of agroclavine with sodium metal and *n*-butanol yielded pyroclavine, costaclavine, festuclavine, and lysergine.[25,26] Festuclavine was also obtained from chanoclavine-I aldehyde,[27] and through total syntheses using nitro-aldol,[28,29] Larock indole,[30] and Giese coupling[31] approaches as key steps. Finally, Vollhardt et al.[32] and Ninomiya et al. used, respectively, a $CpCo(CO)_2$ catalyzed cocyclization of two alkynes and a nitrile, and reductive enamide photocyclization to prepare racemic lysergene.

Analogous to the mesylation of **16**, mesylation of isolysergol (**17**)[17] proceeded smoothly before workup and concentration of the reaction mixture; however, the resulting mesylate **23** was surprisingly unstable compared to the epimeric **19**, complicating its purification and characterization (Scheme 4). Without purification, the mesylate was therefore subjected to nucleophilic displacement with $LiAlH_4$ in THF at reflux, and the desired clavine alkaloid isolysergine (**24**) was isolated in 32% overall yield from **17**. Interestingly, the reaction mixture also contained the novel benzo[*cd*]indol-2(1*H*)-one **25**, which was isolated in 12% yield based on **17**. A $^1H,^1H$-NOESY experiment was critical to support the structural assignment of **25**. Namely, there were through-space correlations between the characteristic aromatic C(4) singlet and the *N*-Me group as well as between the C(12) proton and the cyclopropane methine hydrogens at C(9). The cyclopropane hydrogen were slightly shifted downfield in the ^1H NMR, likely due to the conjugation to the benzo[*cd*]indol-2(1*H*)-one. The oxindole carbonyl carbon typically appears at ca. 171±2 ppm in the ^{13}C NMR, and product **25** also showed this characteristic carbon resonance at 170.2 ppm.



Scheme 4. Syntheses of (±)-isolysergine (**24**) and the novel ergolin-2(3*H*)-one **25**. Mechanistic hypothesis for the formation of **25** by air-oxidation of **28**, and key spectroscopic evidence for the structure of **25**.

Mechanistically, the formation of ergolin-2(3*H*)-one **25** could be rationalized by a deprotonation of indole **23** with $LiAlH_4$, followed by a vinylogous intramolecular displacement of the pendant pseudo-axial mesylate in **26** to provide **28** (Scheme 4).[14,33] Upon workup and exposure to air,[34] the 1,3-dihydrobenzo[*cd*]indole is expected to be oxidized to the oxindole **25**. Structurally related oxindole products have previously been observed as spontaneous air oxidation products and are also obtained from LSD and other lysergates through metabolic or chemical oxidation.[32,35] In addition to the interesting structural similarity of the cyclopropane-containing scaffold of **25** to cycloclavine and the general relevance of the oxidative conversion of the putative intermediate **28** to **25** for the chemistry of ergot alkaloids, substituted benzo[*cd*]indol-2(1*H*)-ones have also

 ©AUTHOR(S)

emerged as potent pharmacological agents, f. ex. in the discovery of BET bromodomain inhibitors, and could therefore be of broader medical significance.[36] Furthermore, the indolo[4,3-*fg*]quinolin-5(4*H*)-one scaffold of **25** has been found in isolates from the medicinal fungus *Xylaria nigripes* (KL.) SACC.[37]

Similarly to the prior synthetic work toward festuclavine and lysergine, isolysergine[21] has previously been prepared from agroclavine by treatment with Na in *n*-BuOH, which also yielded pyroclavine and costaclavine.[26] The latter work also explored the use of methyl lysergate as a source of lysergene, lysergine and isolysergine by $LiAlH_4$ reduction, treatment with sodium butoxide, and catalytic hydrogenation. Finally, Ninomiya et al. used a reductive enamide photocyclization to prepare racemic lysergene and isolysergine, as well as agroclavine and fumigaclavine B through multi-step procedures.[38] In comparison, our routes to lysergine, isolysergine, lysergene, and festuclavine from lysergol and isolysergol are considerably more concise due to the rapid preparation of the precursor alkaloids from readily available starting materials by the hydrogen autotransfer alkylation of 4-bromoindole.

Conclusions


Ergot alkaloids are of high interest for their historical significance, structural complexity and inspiration for organic synthesis strategic and tactical development studies. Their therapeutic potential for the treatment of mental health challenges as well as cancer co-morbidities is under active re-investigation in many biotech companies. We were able to leverage our recent streamlined synthesis of all four stereoisomers of lysergol and isolysergol to establish new approaches to the ergot alkaloids lysergene, lysergine, isolysergine and festuclavine. This pathway complements and expands previous total syntheses of these natural products. In the course of the preparation of isolysergine, we also discovered an interesting new cascade process leading to formation of a cyclopropanated ergolin-2(3*H*)-one as a spontaneous oxidation product of an intermediate 1,3-dihydrobenzo[*cd*]indole that was formed in an intramolecular S_N2-reaction. After resolution of these compounds, we plan to characterize the pharmacological properties of the resulting ten products in comparison to the cycloclavine and lysergol stereoisomers, and further develop a structure-activity relationship that might support the development of non-hallucinogenic ergot alkaloid analogs as alternatives to psilocin and LSD.

Experimental Section


General. Unless stated otherwise, all reactions were performed under an atmosphere of N_2 that was passed through a column (10 × 2 cm) of Drierite®. Prior to use, THF was freshly distilled over sodium/benzophenone, and CH_2Cl_2 was freshly distilled over CaH_2. Et_3N and *i*-$PrNEt_2$ were distilled over CaH_2 and stored over KOH. All glassware and stir bars were dried in an oven for 3 h prior to use. When necessary, degassed solvents were prepared by sparging with N_2 for 1 h. Reactions were monitored by TLC analysis (pre-coated silica gel 60 F254) and spots were visualized (UV lamp 254 nm and 395 nm). Purifications by chromatography were performed on SiO_2. $^1H/^{13}C$ NMR spectra were recorded on Bruker Avance 300/75 MHz, Bruker Avance 400/100 MHz, Bruker Avance 500/125, or Bruker 600/150 MHz instruments. High resolution mass spectra were obtained on a Micromass UK Limited, Q-TOF Ultima API or a Thermo Scientific Exactive Orbitrap LC-MS. Chemical shifts were reported in parts per million (ppm) with the residual solvent peak ($CDCl_3$: 7.26 ppm for ^1H NMR, 77.16 ppm for ^{13}C; CD_3OD: 3.31 ppm for ^1H NMR, 49.00 ppm for ^{13}C NMR) used as the internal standard. Chemical shifts were tabulated as follows: chemical shift, multiplicity (s singlet, d doublet, t triplet, q quartet, dd doublet of doublet,

 ©AUTHOR(S)

dt doublet of triplet, td triplet of doublets, dq doublet of quartets, ddd doublet of doublet of doublet, m multiplet, br s broad singlet), coupling constant(s), and integration. IR spectra were obtained using neat samples on a PerkinElmer 100 IR-ATR spectrometer. Melting points were obtained using a Mel-Temp instrument and are uncorrected. The spectral information of all natural products was checked against the literature references in the isolation papers, and was consistent with this information.




(±)-((6a*RS*,9*RS*)-7-Methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinolin-9-yl)methyl methanesulfonate (19). Methanesulfonyl chloride (0.0460 mL, 0.590 mmol) was added to a solution of **16**[17] (0.0300 g, 0.118 mmol) in pyridine (1.2 mL) at 0 °C. The reaction mixture was stirred for 1 h. Upon completion (TLC control), 1 M NaOH (3 mL) was added, and the solution was extracted with CH_2Cl_2 (3 x 10 mL). The combined organic extracts were washed with H_2O (10 mL) and brine (10 mL), dried ($MgSO_4$), filtered, and concentrated. After removal of pyridine under high-vacuum, the residue was reconcentrated from Al_2O_3-filtered $CHCl_3$ (3x) and dried to remove residual pyridine, providing mesylate **19** (0.0390 g, 0.117 mmol, 99%) as a yellow powder: Mp >150 °C (dec.); IR (ATR) ν_{max} 3039, 2938, 2844, 2796, 1602, 1468, 1445, 1384, 1347, 1227, 1168, 1116, 988, 971, 916 cm^{-1}; ^1H NMR (500 MHz, $CDCl_3$) δ 7.96 (br s, 1 H), 7.25 (d, *J* 10.5 Hz, 1 H), 7.18 (t, *J* 7.20, 1 H), 7.15 (d, *J* 6.5 Hz, 1 H), 6.92 (s, 1 H), 6.28 (s, 1 H), 4.30 (dd, *J* 9.8, 5.3 Hz, 1 H), 4.22 (dd, *J* 9.5, 7.5 Hz, 1 H), 3.52 (dd, *J* 14.5, 5.5 Hz, 1 H), 3.21–3.17 (m, 1 H), 3.16–3.11 (m, 2 H), 3.07 (s, 3 H), 2.73–2.67 (m, 1 H), 2.59 (s, 3 H), 2.39–2.35 (m, 1 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 137.8, 134.2, 128.2, 126.4, 123.5, 118.8, 118.5, 112.5, 111.1, 110.0, 71.3, 63.2, 55.9, 43.9, 37.7, 36.5, 27.0; HRMS (ESI+) *m/z* for $C_{17}H_{21}O_3N_2S$ $[M+H]^+$: calcd 333.1267; found 333.1260.




(±)-Lysergene (20). Potassium *t*-butoxide (0.0672 g, 0.587 mmol) was added in one portion to a solution of **19** (0.0390 g, 0.117 mmol) in DMSO (2 mL) at rt. The reaction mixture was stirred at rt for 2 h, diluted with EtOAc (30 mL) and washed with ice cold brine (3 x 15 mL). The organic layer was dried ($MgSO_4$), filtered, and concentrated. Purification by chromatography on SiO_2 (3:7–2:3 acetone:hexanes with 1% Et_3N) afforded **20** (0.0170 g, 0.0719 mmol, 61%) as a white solid: Mp >200 °C (dec); IR (ATR) ν_{max} 3133, 3087, 3056, 2991, 2944, 2871, 2840, 2788, 2756, 1790, 1797, 1619, 1594, 1459, 1443, 1376, 1344, 1311, 1285, 1224, 1163, 1127, 1113, 1038, 1029 cm^{-1}; ^1H NMR (400 MHz, $CDCl_3$) δ 7.99 (br s, 1 H), 7.27–7.23 (m, 2 H), 7.20 (t, *J* 7.4 Hz, 1 H), 6.98 (s, 1 H), 6.93 (s, 1 H), 5.07 (s, 1 H), 4.96 (s, 1 H), 3.53 (t, *J* 6.8 Hz, 1 H), 3.51 (d, *J* 12.8 Hz, 1 H), 3.30 (dd, *J* 10.8, 5.6 Hz, 1 H), 3.23 (d, *J* 13.2 Hz, 1 H), 2.76 (ddd, *J* 14.4, 11.2, 1.2 Hz, 1 H), 2.59 (s, 1 H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 140.8, 136.5, 134.1, 128.1, 126.6, 123.5, 122.0, 118.6, 112.8, 111.22, 111.18, 110.0, 62.6, 59.0, 43.1, 27.2; HRMS (ESI+) *m/z* for $C_{16}H_{17}N_2$ $[M+H]^+$: calcd 237.1386; found 237.1389.


 ©AUTHOR(S)



(±)-Lysergine (21). A solution of **19** (0.039 g, 0.12 mmol) in THF (1.2 mL) was cooled to 0 °C, and $LiAlH_4$ in THF (0.15 mL, 0.35 mmol, 2.4 M) was added dropwise. The solution was stirred at reflux for 1 h, followed by dropwise addition of EtOAc (3 mL). H_2O (2 mL) was added, and the solution was vigorously stirred for 10 min. The organic layer was separated, and the aq. phase was extracted with EtOAc (2 x 5 mL). The combined organic layers were dried ($MgSO_4$), filtered, and concentrated. Purification by chromatography on SiO_2 (3:7 to 2:3 acetone:hexanes with 1% Et_3N) afforded **21** (0.0161 g, 0.0671 mmol, 56% over 2 steps from **16**) as a fluffy white solid: Mp >200 °C (dec); IR (ATR) ν_{max} 3139, 3094, 3042, 2955, 2925, 2858, 2796, 2762, 1604, 1546, 1463, 1447, 1372, 1341, 1333, 1312, 1300, 1287, 1225, 1167, 1135 cm^{-1}; ^1H NMR (500 MHz, $CDCl_3$) δ 7.89 (br s, 1 H), 7.21–7.17 (m, 3 H), 6.90 (s, 1 H), 6.32 (s, 1 H), 3.53 (dd, *J* 14.5, 5.5 Hz, 1 H), 3.11–3.08 (m, 1 H), 3.00 (dd, *J* 11.0, 5.0 Hz, 1 H), 2.82–2.74 (m, 1 H), 3.69 (app t, *J* 7.5 Hz, 1 H), 2.57 (s, 3 H), 2.16 (t, *J* 10.8 Hz, 1 H), 1.07 (d, *J* 7.0 Hz, 3 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 134.2, 133.7, 128.9, 127.4, 126.4, 123.5, 118.1, 112.2, 111.5, 109.3, 63.3, 61.8, 44.1, 30.8, 27.6, 18.9; HRMS (ESI+) *m/z* for $C_{16}H_{19}N_2$ $[M+H]^+$: calcd 239.1543; found 239.1539.



(±)-Festuclavine (22). To a suspension of **21** (0.015 g, 0.063 mmol) in N_2-sparged MeOH (3 mL) was added 10% Pd/C (0.010 g). The reaction mixture was bubbled with H_2 for 10 min. The mixture was stirred at room temperature under H_2 (1 atm, balloon) for 16 h. Upon completion, the mixture was filtered over Celite®, and the filtrate was concentrated. Purification of the residue by chromatography on SiO_2 (3:7 acetone:hexanes) afforded **22** (0.014 g, 0.058 mmol, 93%) as a white solid: Mp >200 °C (dec); IR (ATR) ν_{max} 3191, 2925, 28851, 2498, 1616, 1441, 1374, 1350, 1291, 1279, 1227, 1154, 1093, 1032, 961 cm^{-1}; ^1H NMR (400 MHz, CD_3OD) δ 7.18 (d, *J* 8.0 Hz, 1 H), 7.07 (t, *J* 7.5 Hz, 1 H), 6.99 (s, 1 H), 6.88 (d, *J* 7.2 Hz, 1 H), 3.57 (app q, *J* 10.4 Hz, 1 H), 3.38–3.34 (m, 1 H), 3.16 (app t, *J* 9.0 Hz, 1 H), 2.90–2.85 (m with an app s at 2.86, 5 H), 2.75 (ddd, *J* 13.2, 5.6, 2.4 Hz, 1 H), 2.56 (t, *J* 18.0 Hz, 1 H), 2.22–2.15 (m, 1 H), 1.29–1.19 (m, 1 H), 1.09 (d, *J* 6.4 Hz, 3 H); ^{13}C NMR (100 MHz, CD_3OD) δ 133.7, 130.1, 125.6, 122.3, 118.5, 112.3, 108.9, 108.0, 67.2, 62.0, 40.7, 39.5, 34.0, 29.3, 25.1, 17.7; HRMS (ESI+) *m/z* for $C_{16}H_{21}N_2$ $[M+H]^+$: calcd 241.1699; found 241.1702.



(±)-Isolysergine (24) and (±)-(1a*SR*,9c*RS*)-3-methyl-1,1a,2,3,6,9c-hexahydro-5*H*-cyclopropa[*c*]indolo[4,3-*fg*]quinolin-5-one (25). Methanesulfonyl chloride (0.046 mL, 0.59 mmol) was added to a solution of isolysergol (**17**) (0.030 g, 0.12 mmol) in pyridine (1.2 mL) at 0 °C. The reaction mixture was stirred for 1 h. Upon completion (TLC control), 0.5 M NaOH (5 mL) was added, and the solution was extracted with CH_2Cl_2 (3 x 10 mL). The

 ©AUTHOR(S)

combined organic extracts were washed with H_2O (10 mL) and brine (10 mL), dried ($MgSO_4$), filtered, and concentrated. The residue was dried under high-vacuum until a dark film was obtained. Subsequent dissolution and reconcentration from Al_2O_3-filtered $CHCl_3$ (3 x 5 mL) afforded **23** which was used immediately in the next step. A solution of **23** (0.039 g, 0.12 mmol) in THF (1.2 mL) was cooled to 0 °C, and $LiAlH_4$ in THF (0.15 mL, 0.35 mmol, 2.4 M) was added dropwise. The reaction mixture was stirred at reflux for 1 h, followed by dropwise addition of EtOAc (3 mL). H_2O (2 mL) was added slowly, and the solution was vigorously stirred for 10 min. The organic layer was separated, and the aq. phase was extracted with EtOAc (2 x 5 mL). The combined organic layers were dried ($MgSO_4$), filtered, and concentrated. Purification by chromatography on SiO_2 (3:7 to 2:3 Acetone:Hexanes with 1% Et_3N) afforded **24** (0.0091 g, 0.038 mmol, 32% over 2 steps) as a white solid and **25** (0.0035 g, 0.014 mmol, 12% over 2 steps) as a yellow solid. **24**: ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.86 (br s, 1 H), 7.19 (d, *J* 8.0 Hz, 1 H), 7.16 (app t, *J* 7.3 Hz, 1 H), 7.12 (d, *J* 6.5 Hz, 1 H), 6.90 (s, 1 H), 6.39 (dd, *J* 4.0, 1.0 Hz, 1 H), 3.44 (dd, *J* 8.5, 4.0 Hz, 1 H), 3.30–3.23 (m, 1 H), 2.78–2. 73 (m, 2 H), 2.64 (dd, *J* 3.5, 1.5 Hz, 1 H), 2.57 (s, 3 H), 2.55–2.49 (m, 1 H), 1.20 (d, *J* 7.0 Hz, 3 H). Spectroscopic data were identical to those reported in a literature reference.[26] **25**: Mp >200 °C; IR (ATR) ν_{max} 3221, 2923, 1686, 1634, 1505, 1482, 1447, 1405, 1303, 1188, 1067 cm^{-1}; ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.67 (d, *J* 8.5 Hz, 1 H), 7.55 (s, 1 H), 7.53 (br s, 1 H), 7.38 (dd, *J* 8.5, 7.0 Hz, 1 H), 6.75 (d, *J* 7.0 Hz, 1 H), 3.89 (dd, *J* 10.5, 1.5 Hz, 1 H), 3.16 (dd, *J* 10.5, 2.0 Hz, 1 H), 2.96 (s, 3 H), 2.64 (td, *J* 8.7, 4.3 Hz, 1 H), 2.66–2.62 (m, 1 H), 1.55 (app q overlapping with residual H_2O peak, *J* 4.7 Hz, 1 H), 1.11 (app q, *J* 4.2 Hz, 1 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.2, 145.2, 137.0, 128.8, 128.3, 127.2, 123.4, 120.6, 116.5, 111.3, 103.4, 48.6, 40.0, 20.9, 11.0, 9.3; HRMS (ESI+) *m/z* for $C_{16}H_{15}ON_2$ $[M+H]^+$: calcd 251.1179; found 251.1177.

Acknowledgements

The authors thank D. Crocker, M. Liang, and T. Maskrey (University of Pittsburgh) for administrative and technical support and the University of Pittsburgh for a Mellon Fellowship (to NRT). Discretionary funding of this work from Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield CT, is gratefully acknowledged.

Supplementary Material

Copies of ^{1}H and ^{13}C NMR spectra are available in the supplementary material file associated with this manuscript.

References

1. Tasker, N. R.; Wipf, P. Biosynthesis, Total Synthesis, and Biological Profiles of Ergot Alkaloids. In: Knölker H.-J., Editor. The Alkaloids: Chemistry and Biology: Academic Press; 2021. p. 1-112. https://doi.org/10.1016/bs.alkal.2020.08.001
2. Schiff, P. L. *Am. J. Pharm. Educ.* **2006**, *70*(5), 98. https://doi.org/10.5688/aj700598
3. Liang, Y.; Wang, H.; Li, C.; Nan, Z.; Li, F. *BMC Vet. Res.* **2017**, *13*(1), 223. https://doi.org/10.1186/s12917-017-1120-6

 ©**AUTHOR(S)**

4. Chen, F. P. L. *Talking Drugs* **2022**, *June 6*, https://www.talkingdrugs.org/the-history-of-hallucinogens-in-china/.
5. Plazas, E.; Faraone, N. *Biomedicines* **2023**, *11*(2), 461. https://doi.org/10.3390/biomedicines11020461
6. Search date 10/13/2023 on https://clinicaltrials.gov.
7. Kornfeld, E. C.; Fornefeld, E. J.; Kline, G. B.; Mann, M. J.; Jones, R. G.; Woodward, R. B. *J. Am. Chem. Soc.* **1954**, *76*, 5256-5257. https://doi.org/10.1021/ja01649a100
8. Jastrzębski, M. K.; Kaczor, A. A.; Wróbel, T. M. *Molecules* **2022**, *27*(21), 7322. https://doi.org/10.3390/molecules27217322
9. McCabe, S. R.; Wipf, P. *Org. Biomol. Chem.* **2016**, *14*, 5894-5913. https://doi.org/10.1039/C6OB00878J
10. Nichols, D. E. *Wiley Interdisciplinary Reviews: Membrane Transport and Signaling* **2012**, *1*(5), 559-579. https://doi.org/10.1002/wmts.42
11. Petronijevic, F.; Timmons, C.; Cuzzupe, A.; Wipf, P. *Chem. Commun.* **2009**, (1), 104-106. https://doi.org/10.1039/B816989F
12. LaPorte, M.; Hong, K. B.; Xu, J.; Wipf, P. *J. Org. Chem.* **2013**, *78*(1), 167-174. https://doi.org/10.1021/jo3022605
13. Xu, J.; Wipf, P. *Org. Biomol. Chem.* **2017**, *15*(34), 7093-7096. https://doi.org/10.1039/C7OB01654A
14. Petronijevic, F. R.; Wipf, P. *J. Am. Chem. Soc.* **2011**, *133*(20), 7704-7707. https://doi.org/10.1021/ja2026882
15. McCabe, S. R.; Wipf, P. *Angew. Chem., Int. Ed.* **2017**, *56*(1), 324-327. https://doi.org/10.1002/anie.201608820
16. McCabe, S. R.; Wipf, P. *Synthesis* **2019**, *51*(1), 213-224. https://doi.org/10.1055/s-0037-1610395
17. Tasker, N. R.; Wipf, P. *Org. Lett.* **2022**, *24*(34), 6341-6345. https://doi.org/10.1021/acs.orglett.2c02596
18. Pazur, E. J.; Tasker, N. R.; Wipf, P. *Org. Biomol. Chem.* **2023**, DOI: 10.1039/D3OB01432K. https://doi.org/10.1039/D3OB01432K
19. Prochazkova, L.; Lippelt, D. P.; Colzato, L. S.; Sjoerds, Z.; Kuchar, M.; Hommel, B. *Psychopharmacol.* **2018**, *235*, 3401–3413. https://doi.org/10.1007/s00213-018-5049-7
20. Abe, M.; Yamatodani, S.; Yamano, T.; Kusumoto, M. *Agricult. Biol. Chem.* **1961**, *25*(7), 594-596. https://doi.org/10.1080/00021369.1961.10857851
21. Schreier, E. *Helv. Chim. Acta* **1958**, *41*, 1984. https://doi.org/10.1002/hlca.19580410708
22. Spilsbury, J. F.; Wilkinson, S. *J. Chem. Soc.* **1961**, 2085-2091. https://doi.org/10.1039/jr9610002085
23. Harris, J. R.; Horwellt, D. C. *Synth. Commun.* **1992**, *22*(7), 995-999. https://doi.org/10.1080/00397919208019288
24. Wheeler, W. J. *Tetrahedron Lett.* **1986**, *27*(30), 3469-3470. https://doi.org/10.1016/S0040-4039(00)84824-8

 ©**AUTHOR(S)**

25. Yamatodani, S.; Abe, M. *Bull. Agricult. Chem. Soc. Japan* **1956**, *20*(2), 95-96. https://doi.org/10.1080/03758397.1956.10857312
26. Nakahara, Y.; Niwaguchi, T.; Ishii, H. *Chem. Pharm. Bull.* **1977**, *25*(7), 1756-1763. https://doi.org/10.1248/cpb.25.1756
27. Matuschek, M.; Wallwey, C.; Wollinsky, B.; Xie, X.; Li, S.-M. *RSC Adv.* **2012**, *2*(9), 3662-3669. https://doi.org/10.1039/c2ra20104f
28. Chaudhuri, S.; Bhunia, S.; Roy, A.; Das, M. K.; Bisai, A. *Org. Lett.* **2018**, *20*(1), 288-291. https://doi.org/10.1021/acs.orglett.7b03683
29. Bhunia, S.; Chaudhuri, S.; Bisai, A. *Chem. Eur. J.* **2017**, *23*(47), 11234-11238. https://doi.org/10.1002/chem.201702459
30. Liu, H.; Zhang, X.; Shan, D.; Pitchakuntla, M.; Ma, Y.; Jia, Y. *Org. Lett.* **2017**, *19*(12), 3323-3326. https://doi.org/10.1021/acs.orglett.7b01504
31. Ge, Y.; Wang, H.; Wang, H.-N.; Yu, S.-S.; Yang, R.; Chen, X.; Zhao, Q.; Chen, G. *Org. Lett.* **2020**, *23*(2), 370-375. https://doi.org/10.1021/acs.orglett.0c03867
32. Saá, C.; Crotts, D. D.; Hsu, G.; Vollhardt, K. P. C. *Synlett* **1994**, 487-489. https://doi.org/10.1055/s-1994-22898
33. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Suntornwat, O. *J. Am. Chem. Soc.* **1990**, *112*(24), 8961-8971. https://doi.org/10.1021/ja00180a048
34. Barton, D. H. R.; Haynes, R. K.; Leclerc, G.; Magnus, P. D.; Menzies, I. D. *J. Chem. Soc., Perkin Trans. 1* **1975**, 2055-2065. https://doi.org/10.1039/p19750002055
35. Troxler, F.; Hofmann, A. *Helv. Chim. Acta* **1959**, *42*(3), 793-802. https://doi.org/10.1002/hlca.19590420321
36. Xue, X.; Zhang, Y.; Liu, Z.; Song, M.; Xing, Y.; Xiang, Q.; Wang, Z.; Tu, Z.; Zhou, Y.; Ding, K.; Xu, Y. *J. Med. Chem.* **2016**, *59*(4), 1565-1579. https://doi.org/10.1021/acs.jmedchem.5b01511
37. Hu, D.; Li, M. "Three New Ergot Alkaloids from the Fruiting Bodies of Xylaria Nigripes (Kl.) Sacc." *Chem. Biodiv.* **2017**, *14*(1), e1600173. https://doi.org/10.1002/cbdv.201600173
38. Ninomiya, I.; Kiguchi, T.; Hashimoto, C.; Naito, T. *Chem. Pharm. Bull.* **1991**, *39*(1), 23-30. https://doi.org/10.1248/cpb.39.23

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)